Senaparib, a PARP 1/2 inhibitor developed by IMPACT Therapeutics, has been approved by China's NMPA for maintenance treatment of advanced ovarian cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.